Constructs trageting CD22 and uses thereof

Patent metadata

Field	Value
Publication number	US-11827672-B2
Application number	US-201917043352-A
Country	US
Kind code	B2
Filing date	Mar 29, 2019
Priority date	Mar 30, 2018
Publication date	Nov 28, 2023
Grant date	Nov 28, 2023

Abstract

Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.

First claim

What is claimed:

1. An anti-CD22 construct comprising an antibody moiety that specifically binds to CD22, wherein the antibody moiety comprises:
(a) a light chain variable region (V L ) comprising a light chain complementarity determining region (LC-CDR) 1, an LC-CDR2, and an LC-CDR3 of the light chain variable region of SEQ ID NO:218 or 212; and
(b) a heavy chain variable region (V H ) comprising a heavy chain complementarity determining region (HC-CDR) 1, an HC-CDR2, and an HC-CDR3 of the heavy chain variable region of SEQ ID NO:219 or 213.

2. The anti-CD22 construct of claim 1 , wherein the antibody moiety comprises one or more of:
the LC-CDR1 having a sequence of HDIRNY (SEQ ID NO:214),
the LC-CDR2 having a sequence of AAS (SEQ ID NO:215),
the LC-CDR3 having a sequence of QQYDGLPLT (SEQ ID NO:216),
the HC-CDR1 having a sequence of GFTFSNYA (SEQ ID NO:209),
the HC-CDR2 having a sequence of ISGSGGST (SEQ ID NO:210), and
the HC-CDR3 having a sequence of ARYGSAAWMDS (SEQ ID NO:217).

3. The anti-CD22 construct of claim 2 , wherein the light chain variable region has a sequence having at least 90% identity to the sequence of DIQLTQSPSSLSTSVGDRVTITCQASHDIRNYLNWYQQKPGKAPNLLIYAASNLQTGVPS RF SGRGSGTDFTLTIS SLQPEDIATYYCQQYDGLPLTFGQGTRLEIKR (SEQ ID NO:218), and/or
wherein the heavy chain variable region has a sequence having at least 90% identity to the sequence of QVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGGST YYADSVKGRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARYGSAAWMDSWGQGTLVT VSS (SEQ ID NO:219).

4. The anti-CD22 construct of claim 1 , wherein the antibody moiety comprises one or more of:
the LC-CDR1 having a sequence of SSNIGNNY (SEQ ID NO:206),
the LC-CDR2 having a sequence of ENN (SEQ ID NO:207),
the LC-CDR3 having a sequence of GTWDSSLSAGAV (SEQ ID NO:208),
the HC-CDR1 having a sequence of GFTFSNYA (SEQ ID NO:209),
the HC-CDR2 having a sequence of ISGSGGST (SEQ ID NO:210), and
the HC-CDR3 having a sequence of ARPYYDD (SEQ ID NO:211).

5. The anti-CD22 construct of claim 1 or 4 , wherein the light chain variable region has a sequence having at least 90% identity to the sequence of QSVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENNKRPSGIP DRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGAVFGGGTKLTVLG (SEQ ID NO:212), and/or
wherein the heavy chain variable region has a sequence having at least 90% identity to the sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAISGSGGST YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPYYDDWGQGTLVTVS S (SEQ ID NO:213).

6. The anti-CD22 construct of claim 1 , wherein the construct is a full-length antibody, a Fab, a Fab′, a F(ab′)2, an Fv, a single chain Fv (scFv) antibody, a tandem scFv, a diabody (Db), a single chain diabody (scDb), a dual-affinity retargeting (DART) antibody, a dual variable domain (DVD) antibody, a knob-into-hole (KiH) antibody, a dock and lock (DNL) antibody, a chemically cross-linked antibody, a heteromultimeric antibody, or a heteroconjugate antibody.

7. The anti-CD22 construct of claim 1 , wherein the construct further comprises a second antibody moiety that specifically binds to a second antigen, and wherein the second antigen is an antigen on the surface of a T cell, a natural killer cell, a neutrophil, a monocyte, a macrophage, or a dendritic cell.

8. A chimeric anti-CD22 construct comprising the anti-CD22 construct of claim 1 , wherein the anti-CD22 construct is either (a) a chimeric antigen receptor (CAR) or (b) a chimeric antibody-T cell receptor (caTCR) comprising an extracellular domain that binds to CD22 and a T cell receptor (TCR) module (TCRM) comprising TCR transmembrane domains.

9. The anti-CD22 construct of claim 8 , wherein the anti-CD22 construct is a CAR, and wherein:
(A) the CAR comprises an anti-CD22 antibody moiety, a transmembrane domain, and an immune cell signaling domain, wherein the anti-CD22 antibody moiety is a scFv comprising the LC-CDR1, the LC-CDR2, and the LC-CDR3 having the sequences of SEQ ID NOS:214-216, respectively, the HC-CDR1, the HC-CDR2, and the HC-CDR3 having the sequences of SEQ ID NOS:209, 210, and 217, respectively; or
(b) the CAR comprises an anti-CD22 antibody moiety, a transmembrane domain, and an immune cell signaling domain, wherein the anti-CD22 antibody moiety is a scFv comprising the LC-CDR1, the LC-CDR2, and the LC-CDR3 having the sequences of SEQ ID NOS:206-208, respectively, the HC-CDR1, the HC-CDR2, and the HC-CDR3 having the sequences of SEQ ID NOS:209-211, respectively.

10. The anti-CD22 construct of claim 8 , wherein the anti-CD22 construct is a caTCR, and wherein:
(a) the caTCR comprises LC-CDR1, LC-CDR2, and LC-CDR3 having the sequences of SEQ ID NOS:214-216, respectively, and HC-CDR1, HC-CDR2, and HC-CDR3 having the sequences of SEQ ID NOS:209, 210, and 217, respectively; or
(b) the caTCR comprises LC-CDR1, LC-CDR2, and LC-CDR3 having the sequences of SEQ ID NOS:206-208, respectively, and HC-CDR1, HC-CDR2, and HC-CDR3 having the sequences of SEQ ID NOS:209-211 respectively.

11. The anti-CD22 construct of claim 8 , wherein the anti-CD22 construct is a caTCR, and wherein:
(1) the extracellular domain comprises:
(a) a first polypeptide comprising a first antigen-binding region comprising a heavy chain variable region (V H ) and a C H 1 constant domain; and
(b) a second polypeptide chain comprising a second antigen-binding region comprising a light chain variable region (V L ) and a C L constant domain,
wherein the V H and the C H 1 constant domain of the first antigen-binding region and the V L and the C L constant domain of the second antigen-binding region form a Fab-like antigen-binding module that specifically binds to CD22; or

(2) the extracellular domain further comprises at least one additional antibody moiety that specifically binds to at least one non-CD22 antigen.

12. The anti-CD22 construct of claim 8 , wherein the anti-CD22 construct is a caTCR, and wherein the caTCR is expressed in combination with a chimeric signaling receptor (CSR).

13. An anti-CD22 construct which is a chimeric signaling receptor (CSR) further comprising:
(a) the anti-CD22 construct of claim 1 ;
(b) a transmembrane module; and
(c) a co-stimulatory immune cell signaling module that is capable of providing a costimulatory signal to the immune cell,
wherein the CSR lacks a functional primary immune cell signaling domain.

14. The anti-CD22 construct of claim 13 , wherein:
(a) the anti-CD22 antibody moiety comprises the LC-CDR1, the LC-CDR2, and the LC-CDR3 having the sequences of SEQ ID NOS:214-216, respectively, the HC-CDR1, the HC-CDR2, and the HC-CDR3 having the sequences of SEQ ID NOS:209, 210, and 217, respectively; or
(b) the anti-CD22 antibody moiety comprises the LC-CDR1, the LC-CDR2, and the LC-CDR3 having the sequences of SEQ ID NOS:206-208, respectively, the HC-CDR1, the HC-CDR2, and the HC-CDR3 having the sequences of SEQ ID NOS:209-211, respectively.

15. The anti-CD22 construct of any one of claim 13 , wherein the CSR is expressed in combination with a caTCR or CAR.

16. A nucleic acid molecule encoding one or more polypeptides contained in the anti-CD22 construct of claim 1 .

17. A pharmaceutical composition comprising a therapeutically effective amount of the anti-CD22 construct of claim 1 and one or more pharmaceutically acceptable carriers or excipients.

18. A method of treating a B-cell malignancy or a disease or disorder characterized by CD22 overexpression in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the anti-CD22 construct of claim 1 .

Assignees

• Eureka Therapeutics Inc

Inventors

• Cui Jun
• Zhang Pengbo
• Xu Yiyang
• Li Shan
• Xu Yixiang
• Xiong Guangyan
• Yun Hongruo
• Liu Lianxing
• Ge Xiaomei
• Xu Shaohua
• Liu Hong
• Morales Javier

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• A61K40/4212

  CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title